Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
Industry, Sector and Symbol:
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ARRY
- CUSIP: 04269X10
- Web: www.arraybiopharma.com
- Market Cap: $1.39 billion
- Outstanding Shares: 170,800,000
- 50 Day Moving Avg: $8.17
- 200 Day Moving Avg: $9.27
- 52 Week Range: $3.10 - $13.40
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.17
- P/E Growth: -1.09
- Annual Revenue: $41.51 million
- Price / Sales: 33.58
- Book Value: $0.16 per share
- Price / Book: 51.00
- EBIDTA: ($96,300,000.00)
- Net Margins: -58.57%
- Return on Assets: -49.54%
- Debt-to-Equity Ratio: 2.26%
- Current Ratio: 4.10%
- Quick Ratio: 4.10%
- Average Volume: 4.07 million shs.
- Beta: 2.12
- Short Ratio: 4.49
Frequently Asked Questions for Array Biopharma (NASDAQ:ARRY)
What is Array Biopharma's stock symbol?
Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."
How were Array Biopharma's earnings last quarter?
Array Biopharma Inc (NASDAQ:ARRY) posted its earnings results on Wednesday, May, 10th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05. The company earned $33.28 million during the quarter, compared to analyst estimates of $38.28 million. The company's revenue was down 22.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.16) earnings per share. View Array Biopharma's Earnings History.
Where is Array Biopharma's stock going? Where will Array Biopharma's stock price be in 2017?
8 analysts have issued twelve-month price objectives for Array Biopharma's shares. Their predictions range from $7.00 to $15.00. On average, they anticipate Array Biopharma's share price to reach $11.38 in the next year. View Analyst Ratings for Array Biopharma.
What are analysts saying about Array Biopharma stock?
Here are some recent quotes from research analysts about Array Biopharma stock:
- 1. Cowen and Company analysts commented, "We see ARRY's decision to withdraw the NRAS NDA as prudent given the known modest efficacy benefit. The NRAS-mutant melanoma opportunity represented a modest 6% of our base model DCF, thus we lower our PT modestly from $15 to $14. We view recent share weakness and the passing of this 'risk' event as an especially attractive opportunity to firmly reiterate our Outperform rating on ARRY shares." (3/20/2017)
- 2. According to Zacks Investment Research, "Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. " (1/31/2017)
Are investors shorting Array Biopharma?
Array Biopharma saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 19,794,836 shares, an increase of 10.1% from the April 13th total of 17,983,716 shares. Based on an average daily trading volume, of 2,465,514 shares, the days-to-cover ratio is presently 8.0 days. Currently, 11.7% of the shares of the company are short sold.
Who are some of Array Biopharma's key competitors?
Some companies that are related to Array Biopharma include Intrexon Corp (XON), SAGE Therapeutics (SAGE), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), Clovis Oncology (CLVS), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Axovant Sciences Ltd (AXON), Portola Pharmaceuticals (PTLA), Theravance Biopharma (TBPH), Prothena Co. PLC (PRTA), FibroGen (FGEN), Cambrex (CBM), Sarepta Therapeutics (SRPT), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), Lexicon Pharmaceuticals (LXRX) and Radius Health (RDUS).
Who are Array Biopharma's key executives?
Array Biopharma's management team includes the folowing people:
- Kyle A. Lefkoff, Independent Chairman of the Board
- Ron R. Squarer, Chief Executive Officer, Director
- Jason Haddock, Chief Financial Officer
- Andrew R. Robbins, Chief Operating Officer
- Nicholas A. Saccomano Ph.D., Chief Scientific Officer
- John R. Moore, Vice President, General Counsel, Secretary
- Victor Sandor, Chief Medical Officer
- Shalini Sharp, Director
- Charles M. Baum M.D., Ph.D., Independent Director
- Gwendolyn A. Fyfe M.D., Independent Director
Who owns Array Biopharma stock?
Array Biopharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (0.00%),
VANGUARD GROUP INC
(10.05%), Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.86%) and Pinnacle Associates Ltd. (0.00%). Company insiders that own Array Biopharma stock include Charles M Baum and Redmile Group, Llc. View Institutional Ownership Trends for Array Biopharma.
Who sold Array Biopharma stock? Who is selling Array Biopharma stock?
Array Biopharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Teachers Advisors LLC, Metropolitan Life Insurance Co. NY, Credit Suisse AG, Candriam Luxembourg S.C.A., AXA, Sphera Funds Management LTD. and TIAA CREF Investment Management LLC. Company insiders that have sold Array Biopharma stock in the last year include Charles M Baum and Redmile Group, Llc. View Insider Buying and Selling for Array Biopharma.
Who bought Array Biopharma stock? Who is buying Array Biopharma stock?
Array Biopharma's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., State Street Corp, Cambiar Investors LLC, Canada Pension Plan Investment Board, Goldman Sachs Group Inc., MARSHALL WACE ASIA Ltd and Marshall Wace North America L.P.. View Insider Buying and Selling for Array Biopharma.
How do I buy Array Biopharma stock?
Shares of Array Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Array Biopharma's stock price today?
MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Array Biopharma stock can currently be purchased for approximately $8.16.
Earnings History for Array Biopharma (NASDAQ:ARRY)Earnings History by Quarter for Array Biopharma (NASDAQ ARRY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q3 2017||($0.16)||($0.21)||$38.28 million||$33.28 million||View||N/A|
|2/9/2017||Q2 2017||($0.18)||($0.14)||$31.90 million||$44.50 million||View||Listen|
|11/1/2016||Q117||($0.16)||($0.20)||$32.47 million||$39.30 million||View||Listen|
|8/4/2016||Q416||($0.14)||($0.17)||$41.51 million||$43.20 million||View||Listen|
|5/3/2016||Q316||($0.12)||($0.16)||$30.35 million||$43.00 million||View||Listen|
|2/2/2016||Q216||($0.06)||($0.17)||$32.70 million||$35.40 million||View||Listen|
|11/4/2015||Q116||($0.18)||($0.15)||$14.02 million||$16.20 million||View||Listen|
|8/3/2015||Q415||($0.16)||($0.09)||$10.29 million||$12.30 million||View||Listen|
|5/4/2015||Q315||($0.01)||$0.37||$6.00 million||$6.60 million||View||Listen|
|2/3/2015||Q215||($0.20)||($0.06)||$10.20 million||$26.92 million||View||Listen|
|11/4/2014||Q115||($0.22)||($0.21)||$6.35 million||$6.07 million||View||Listen|
|8/12/2014||Q414||($0.23)||($0.22)||$8.10 million||$6.00 million||View||Listen|
|4/29/2014||Q314||($0.21)||($0.20)||$9.40 million||$7.80 million||View||Listen|
|2/4/2014||Q214||($0.16)||($0.13)||$13.49 million||$14.10 million||View||Listen|
|10/31/2013||Q114||($0.18)||($0.13)||$11.20 million||$14.20 million||View||Listen|
|8/7/2013||Q4 2013||($0.13)||($0.06)||$16.13 million||$25.40 million||View||Listen|
|5/6/2013||Q3 2013||($0.14)||($0.19)||$14.54 million||$10.00 million||View||Listen|
|2/4/2013||Q2 2013||($0.14)||($0.10)||$16.52 million||$18.40 million||View||Listen|
|10/29/2012||Q113||($0.15)||($0.13)||$16.70 million||$15.80 million||View||N/A|
Earnings Estimates for Array Biopharma (NASDAQ:ARRY)
2017 EPS Consensus Estimate: ($0.94)
2018 EPS Consensus Estimate: ($0.91)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Array Biopharma (NASDAQ:ARRY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Array Biopharma (NASDAQ:ARRY)
Insider Ownership Percentage: 2.60%Insider Trades by Quarter for Array Biopharma (NASDAQ:ARRY)
Institutional Ownership Percentage: 88.58%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/28/2017||Charles M Baum||Director||Sell||25,000||$9.27||$231,750.00|| |
|9/28/2016||Redmile Group, Llc||Major Shareholder||Sell||2,492,578||$6.36||$15,852,796.08|| |
|9/15/2016||Redmile Group, Llc||Major Shareholder||Buy||400,000||$3.51||$1,404,000.00|| |
|1/20/2016||Redmile Group, Llc||Major Shareholder||Buy||300,000||$3.19||$957,000.00|| |
|1/12/2016||Redmile Group, Llc||Major Shareholder||Buy||75,000||$3.60||$270,000.00|| |
|1/11/2016||Redmile Group, Llc||Major Shareholder||Buy||925,000||$3.67||$3,394,750.00|| |
|10/1/2015||Redmile Group, Llc||Major Shareholder||Buy||782,592||$4.58||$3,584,271.36|| |
|8/25/2015||Redmile Group, Llc||Major Shareholder||Buy||790,000||$5.38||$4,250,200.00|| |
|8/10/2015||Redmile Group, Llc||Major Shareholder||Buy||1,048,993||$5.80||$6,084,159.40|| |
|3/3/2015||Kyle Lefkoff||Director||Sell||70,000||$8.00||$560,000.00|| |
|3/2/2015||Andrews R Robbins||SVP||Sell||21,576||$8.25||$178,002.00|| |
|3/2/2015||Ron Squarer||CEO||Sell||40,000||$8.25||$330,000.00|| |
|9/16/2013||Liam Ratcliffe||Director||Sell||1,673,172||$6.08||$10,172,885.76|| |
|9/6/2013||Liam Ratcliffe||Director||Sell||577,286||$5.79||$3,342,485.94|| |
|8/2/2013||John R Moore||VP||Sell||75,384||$7.02||$529,195.68|| |
|7/23/2013||John R Moore||VP||Sell||5,000||$6.50||$32,500.00|| |
Headline Trends for Array Biopharma (NASDAQ:ARRY)
Latest Headlines for Array Biopharma (NASDAQ:ARRY)
Array Biopharma (ARRY) Chart for Tuesday, May, 30, 2017